Safinamide (Newron Pharmaceuticals).
Safinamide (formerly PNU-151774E), a sodium and calcium channel modulator that also inhibits monoamine oxidase B (MAOB), is under development by Newron Pharmaceuticals for the potential treatment of epilepsy, Parkinson's disease (PD), pain and stroke [345222], [348351]. Phase I trials for epilepsy and PD have been completed, and dose-finding studies for both indications had commenced in March 2001 [401685]. The compound was previously developed by Pharmacia & Upjohn (P&U) for the potential treatment of epilepsy, an indication for which it initially reached phase I trials [294891], [345007]. Newron acquired the rights to safinamide from P&U at the end of 1998. Results from two phase I trials of the compound (single ascending dose and steady state at three doses), completed in March 2000, demonstrated that the drug is well tolerated with good bioavailability and linear pharmacokinetics [359652].
Chazot
P L
PL
University of Sunderland School of Sciences, Tyne and Wear, UK. Paul.Chazot@sunderland.ac.uk
D000409:Alanine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D000927:Anticonvulsants / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000978:Antiparkinson Agents / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D001596:Benzylamines / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D002986:Clinical Trials as Topic; D000075202:Contraindications; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy; D013329:Structure-Activity Relationship
D000927:Anticonvulsants; D000978:Antiparkinson Agents; D001596:Benzylamines; C092797:safinamide; D000409:Alanine